Aromatase inhibitors as potential cancer chemopreventives

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 1, 1998, Pages 65-78

  Kelloff, Gary J ^a   Lubet, Ronald A ^a   Lieberman, Ronald ^a   Eisenhauer, Karen ^b   Steele, Vernon E ^a   Crowell, James A ^a   Hawk, Ernest T ^a   Boone, Charles W ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYLESTR 4 ENE 3,17 DIONE; 4,4' (FLUORO 1H 1,2,4 TRIAZOL 1 YLMETHYLENE)BIS BENZONITRILE; [[3ALPHA ETHYL 9 (ETHYLTHIO) 2,3,3ALPHA,4,5,6 HEXAHYDRO 1H PHENALEN 2 YL]METHYL] 1H IMIDAZOLE; AMINOGLUTETHIMIDE; ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ATAMESTANE; CGP 47645; CORTICOTROPIN; CYTOCHROME P450; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; GONADOTROPIN; MEGESTROL ACETATE; MINAMESTANE; ORG 33201; R 75521; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOROZOLE; ZK 95639;

BREAST CANCER; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOMNOLENCE; SUBCUTANEOUS DRUG ADMINISTRATION;

AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGENS; FEMALE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 0031908096     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Kelloff, G J., Fay, J. R., Steels, V. E., Lubet, R. A., Boone, C. W., Crowell, J. A., and Sigman, C. C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev., 5: 657-666, 1996.
2. Kelloff, G. J., Lubet, R A., Fay, J. R., Steele, V. E., Boone, C W., Crowell, J. A., and Sigman, C. C. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev., 6: 267-282, 1997.
3. Kelloff, G. J., Hawk, E. T, Karp, J. E, Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., and Sigman, C. C. Progress in clinical chemoprevention. Semin. Oncol., 24: 241-252, 1997.
4. Cole, P. A., and Robinson, C. H. Mechanism and inhibition of cytochrome P-450 aromatase. J. Med Chem., 33: 2933-2942, 1990.
5. Santen, R. J. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives. Breast Cancer Res. Treat., 7S: 23-35, 1986.
6. Simpson, E. R., Mahendroo, M. S., Means, G D., Kilgore, M. W., Hinshelwood, M. M., Graham-Lorence, S., Amarneh, B., Ito, Y., Fisher, C. R., Michael, M. D., Mendelson, C. R., and Bulun, S. E. Aromatese cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev., 15: 342-355, 1994
7. Henderson, B. E., Ross, R., and Bernstein, L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res., 48: 246-253, 1988.
8. Spicer, D. V., and Pike, M. C. Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res. Treat., 28: 179-193, 1993.
9. Reid, S. E., Murthy, M. S., Kaufman, M., and Scanlon, E. F. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br. J. Surg., 83: 1037-1046, 1996.
10. Lippman, M. E., and Dickson, R. B. Growth control of normal and malignant breast epithelium. Prog. Clin. Biol. Res., 354: 147-178, 1990.
11. Lupulescu, A. Estrogen use and cancer incidence: a review. Cancer Invest., 13: 287-295, 1995.
12. Miller, W. R. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev., 16: 83-93, 1989.
13. Henderson, I. C., and Canellos, G. P. Cancer of the breast. The past decade. N. Engl. J. Med., 302, 17-30, 1980.
14. Roy, D., and Abul-Hajj, Y. J. Estrogen-nucleic acid adducts: guanine is major site for interaction between 3,4-estrone quinone and COIII gene. Carcinogenesis (Lond.), 18: 1247-1249, 1997.
15. Esteban, J. M., Warsi, Z., Haniu, M., Hall, P., Shively, J. E., and Chen, S. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am. J. Pathol., 140: 337-343, 1992.
16. Miller, W. R., and Mullen, P. Factors influencing aromatase activity in the breast. J. Steroid Biochem. Mol. Biol., 44: 597-604, 1993.
17. Bulun, S. E., and Simpson, E. R. Regulation of aromatase expression in human tissues. Breast Cancer Res. Treat., 30: 19-29, 1994.
18. Miller, W. R. Aromatase activity in breast tissue. J Steroid Biochem. Mol. Biol., 39: 783-790, 1991
19. Berstein, L. M., Larionov, A. A., Kyshtoobaeva, A. S., Pozharisski, K. M., Semiglazov, V. F., and Ivanova, O. A. Aromatase in breast cancer tissue: localization and relationship with reproductive status of patients. J. Cancer Res. Clin. Oncol., 122: 495-498, 1996.
20. Santen, R. J., Martel, J., Hoagland, M, Naftolin, F., Roa, L., Harada, N, Hafer, L., Zaino, R., and Santner, S. J. Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab., 79: 627-632, 1994.
21. Allred, D. C., O'Connell, P., and Fuqua, S. A. W Biomarkers in early breast neoplasia. J. Cell. Biochem, 17G: 125-131, 1993.
22. Diab, S. G., Castles, C. G., and Fuqua, S. A W. Role of altered estrogen receptors in breast cancer., In: Vedeckis, W. V. (ed.). Hormones and Cancer, pp. 261-281. Boston: Birkhauser, 1996.
23. Frykberg, E. R., and Bland, K. I. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer (Phila.), 74: 350-361, 1994.
24. Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339: 1-15, 1992.
25. Jordan, V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur. J. Cancer Clin. Oncol., 12: 419-424, 1976.
26. Gottardis, M. M., and Jordan, V. C Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47: 4020-4024, 1987.
27. Moon, R. C., Steele, V. E., Kelloff, G. J., Thomas, C. P., Detrisac, C. J., Mehta, R. G., and Lubet, R. A. Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers, toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res., 14: 889-893, 1994.
28. Schieweck, K., Bhatnagar, A. S., and Matter, A. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. Cancer Res., 48: 834-838, 1988.
29. De Coster, R., Wouters, W., Bowden, C. R., Vanden Bossche, H, Bruynseels, J., Tuman, R. W., Van Ginckel, R., Snoeck, E., Van Peer, A., and Janssen, P. A. J. New non-steroidal aromatase inhibitors: focus on R76713, J. Steroid Biochem. Mol. Biol., 37: 335-341, 1990.
30. Rao, A. R., Das, M. G., and Das, P. Inhibitory action of aminoglutethimide on DMBA-induced mammary carcinogenesis. Oncology (Basel), 42: 119-121, 1985.
31. Lubet, R A., Steele, V. E., Casebolt, T. L., Eto, I., Kelloff, G. J., and Grubbs, C. J. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis (Lond.), 15, 2775-2780, 1994.
32. Kelloff, G. J., Boone, C W., Steele, V. E., Crowell, J. A., Lubet, R., and Sigman, C. C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 54 (Suppl.): 2015S-2024S, 1994.
33. Montironi, R., Bostwick, D. G., Bonkhoff, H., Cockett, A T. K., Helpap, B., Troncoso, P, and Waters, D. Workgroup 1. Origins of prostate cancer. Cancer (Phila.), 78: 362-365, 1996.
34. Bostwick, D. G. Prospective origins of prostate carcinoma. Prostatic intra-epithelial neoplasia and atypical adenomatous hyperplasia. Cancer (Phila.), 78: 330-336, 1996.
35. Farnsworth, W. E. Roles of estrogen and SHBG in prostate physiology. Prostate, 28: 17-23, 1996.
36. Brodie, A. M. H., Son, C., King, D. A., Meyer, K. M., and Inkster, S. E. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism. Cancer Res., 49: 6551-6555, 1989.
37. Bartsch, W., Klein, H., Sturenburg, H-J., and Voigt, K-D. Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition. J. Steroid Biochem., 27: 557-564, 1987.
38. Stone, N. N., Fair, W. R., and Fishman, J. Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate, 9, 311-318, 1986
39. Stone, N. N., Laudone, V. P., Fair, W. R., and Fishman, J. Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions. Urol. Res., 15: 165-167, 1987.
40. Ekman, P., Barrack, E. R, Greene, G. L., Jensen, E. V., and Walsh, P C. Estrogen receptors in human prostate: evidence for multiple binding sites. J. Clin. Endocrinol. Metab., 57, 166-176, 1983.
41. Etreby, M. F. E., and Habenicht, U-F. The function and the role of aromatase inhibitors in the treatment of BPH. Prog. Clin. Biol. Res., 386: 209-230, 1994.
42. De Coster, R., Wouters, W., and Bruynseels, J. P450-dependent enzymes as targets for prostate cancer therapy. J. Steroid Biochem. Mol. Biol., 56: 133-143, 1996.
43. Trachtenberg, J., Hicks, L. L., and Walsh, P. C. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. J. Clin. Invest., 65: 1051-1059, 1980.
44. Winter, M. L., and Liehr, J. G. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Toxicol. Appl. Pharmacol., 136: 211-219, 1996.
45. Krieg, M., Nass, R., and Tunn, S. Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate J. Clin. Endocrinol. Metab., 77: 375-381, 1993.
46. Gingell, J. C., Knonagel, H., Kurth, K. H., Tunn, U W., Ackermann, R., Funke, P. J., Guddat, H. M., Nagel, R., Jacobi, G. H., Senge, T., Bartsch, G., Kaisary, A. V., Hauri, D., and Schroder, F. H. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. J. Urol., 154: 399-401, 1995.
47. Leav, I., Ho, S-M., Ofner, P., Merk, F. B., Kwan, P W-L, and Damassa, D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of noble rats J Natl. Cancer Inst. (Bethesda), 80: 1045-1053, 1988.
48. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration Cancer Res., 37: 1929-1933, 1977.
49. Noble, R. L Prostate carcinoma of the Nb rat in relation to hormones. Int. Rev. Exp. Pathol., 23: 113-159, 1982.
50. Drago, J. R. The induction of NB rat prostatic carcinomas. Anticancer Res., 4: 255-256, 1984.
51. Suzuki, K, Ito, K, Suzuki, T., Honma, S., and Yamanaka, H. Synergistic effects of estrogen and androgen on the prostate. Effects of estrogen on androgen-and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. Prostate, 26: 151-163, 1995.
52. Suzuki, K., Takezawa, Y., Suzuki, T., Honma, S., and Yamanaka, H. Synergistic effects of estrogen with androgen on the prostate: effects of estrogen on the prostate of androgen-administered rats and 5-α-reductase activity Prostate, 25: 169-176, 1994.
53. 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17β and testosterone. Carcinogenesis (Lond ), 16: 951-954, 1995.
54. Spencer, G. G., Wood, D., and Gupta, R. C. DNA adducts in human normal and tumorous prostate biopsies. Proc. Annu. Meet. Am. Assoc. Cancer. Res., 35, 96, 1994.
55. 32P-postlabeling. Int. J. Oncol, 7: 245-248, 1995.
56. Castagnetta, L. A. M., and Carruba, G. Human prostate cancer: a direct role for oestrogens. CIBA Found. Symp., 191: 269-289, 1995.
57. Davies, J. H., Dowsett M., Jacobs, S., Coombes, R. C., Hedley, A., and Shearer, R. J. Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. Br. J. Cancer, 66: 139-142, 1992.
58. Vanden Bossche, H., Moereels, H., and Koymans, L. M. H. Aromatase inhibitors: mechanisms for non-steroidal inhibitors. Breast Cancer Res. Treat., 30: 43-55, 1994
59. Castiglione-Gertsch, M. New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity. Eur. J Cancer, 32A: 393-395, 1996.
60. Ibrahim, N. K., and Buzdar, A. U Aromatase inhibitors: current status. Am. J Clin. Oncol., 18: 407-417, 1995.
61. Santen, R J. Estrogen synthesis inhibitors: From "off the rack" to haute couture. J. Clin. Endocrinol. Metab, 77: 316-318, 1993.
62. Brodie, A M. H. Aromatase inhibitors in the treatment of breast cancer J. Steroid Biochem. Mol. Biol., 49: 281-287, 1994
63. Brodie, A. M. H., and Santen, R. J. Aromatase and its inhibitors in breast cancer treatment: overview and perspective. Breast Cancer Res. Treat., 30: 1-6, 1994
64. Brueggemeier, R. W. Aromatase inhibitors: mechanisms of steroidal inhibitors. Breast Cancer Res. Treat., 30: 31-42, 1994.
65. Hartmann, R W., Grun, G., Bartz, U., and Palzer, M. Evaluation of the racemate and the enantiomers of a new highly active and selective aromatase inhibitor of the aminoglutethimide type. J. Steroid Biochem. Mol. Biol., 43: 641-648, 1992.
66. Foster, A. B., Jarman, M., Leung, C-S., Rowlands, M. G., Taylor, G. N., Plevey, R. G., and Sampson, P. Analogues of aminoglutethimide: selective inhibition of aromatase J. Med. Chem., 28: 200-204, 1985.
67. Yamamoto, T., Urabe, M., Tamura, T., Kitawaki, J, Honjo, H., and Okada, H. Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat Anticancer Res., 11: 1999-2002, 1991.
68. Dowsett, M., MacNeill, F, Mehta, A., Newton, C., Haynes, B., Jones, A., Jarman, M., Lonning, P., Powles, T. J., and Coombes, R C. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients. Br. J. Cancer, 64: 887-894, 1991.
69. MacNeill, F. A., Jones, A. L., Jacobs, S., Lonning, P. E., Powles, T J., and Dowsett, M The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer, 66: 692-697, 1992.
70. Goss, P. E., and Gwyn, K. M. E. H. Current perspectives on aromatase inhibitors in breast cancer J. Clin. Oncol., 12: 2460-2470, 1994
71. Steele, R E., Mellor, L. B, Sawyer, W. K., Wasvary, J. M., and Browne, L. J., In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A Steroids, 50: 147-163, 1987.
72. Yano, S., Tanaka, M., and Nakao, K Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells. Eur. J. Pharmacol, 289: 217-222, 1995.
73. Gunson, D E., Steele, R. E., and Chau, R. Y. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br. J. Cancer, 72: 72-75, 1995.
74. Houjou, T., Wada, T., and Yasutomi, M. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor. Clin. Ther., 15: 137-147, 1993.
75. Tanaka, M, Yano, S, Hasegawa, Y., and Nakao, K. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor. Arzneimittelforschung, 44: 774-778, 1994.
76. Tominaga, T., Yoshida, Y., Shimozuma, K., Hayashi, K., and Kosaki, G. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats. Eur. J. Cancer, 26: 600-603, 1990.
77. Lipton, A., Harvey, H A, Demers, L. M, Hanagan, J. R., Mulagha, M T, Kochak, G. M., Fitzsimmons, S., Sanders, S. I., and Santen, R. J. A Phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer (Phila.), 65: 1279-1285, 1990.
78. Lonning, P. E., Jacobs, S., Jones, A., Haynes, B., Powles, T., and Dowsett, M The influence of CGS-16949A on peripheral aromatisation in breast cancer patients. Br. J. Cancer, 63: 789-793, 1991.
79. Demers, L. M. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients Breast Cancer Res Treat., 30: 95-102, 1994.
80. Dowsett, M., Smithers, D., Moore, J, Trunet, P. F., Coombes, R. C., Powles, T. J., Rubens, R., and Smith, I E. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur. J. Cancer, 30A: 1453-1458, 1994.
81. Stein, R. C., Dowsett, M., Davenport, J., Hedley, A., Ford, H. T., Gazet, J-C., and Coombes, R. C. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res., 50: 1381-1384, 1990.
82. Bonnefoi, H. R., Smith, I. E., Dowsett, M., Trunet, P. F., Houston, S. J., da Luz, R. J., Rubens, R. D., Coombes, R. C., and Powles, T. J. Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br. J. Cancer, 73: 539-542, 1996.
83. Bruynseels, J., De Coster, R., Van Rooy, P., Wouters, W., Coene, M. C., Snoeck, E, Raeymaekers, A., Freyne, E., Sanz, G., Bussche, G. V., Bassche, H. V., Willlemsens, G, and Janssen, P. A. J. R 75251, a new inhibitor of steroid biosynthesis. Prostate, 16: 345-357, 1990.
84. De Coster, R., Wouters, W, Van Ginckel, R., End, D., Krekels, M., Coene, M-C, and Bowden, C. Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown. J. Steroid Biochem. Mol. Biol., 43: 197-201, 1992.
85. Dijkman, G. A, Van Moorselaar, R. J. A., Van Ginckel, R, Van Stratum, P., Wouters, L., Debruyne, F. M J, Schalken, J. A., and De Coster, R. Antitumoral effects of liarozole in androgen-dependent and -independent R3327-Dunning prostate adenocarcinomas. J. Urol. 151: 217-222, 1994.
86. Seidmon, E. J., Trump, D. L., Kreis, W., Hall, S W., Kurman, M R., Ouyang, S. P., Wu, J., and Kremer, A. B Phase I/III dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. Ann. Surg. Oncol., 2: 550-556, 1995.
87. Van Wauwe, J., Coene, M-C., Coon, W., Goossens, J., Lauwers, W., LeJeim, L., Van Hom, C, and Van Nyen, G. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem. Pharmacol., 47: 737-741, 1994.
88. Van Wauwe, J., Van Nyen, G., Coene, M-C., Stoppie, P., Cools, W., Goossens, J., Borghgraef, P., and Janssen, P. A. J. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J. Pharmacol. Exp. Ther., 261: 773-779, 1992.
89. Yates, R. A., Dowsett, M., Fisher, G. V., Selen, A, and Wyld, P J. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br. J. Cancer, 73: 543-548, 1996.
90. Plourde, P V., Dyroff, M., and Dukes, M. Arimidex. A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat., 30: 103-111, 1994.
91. Jonat, W, Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R, and Azab, M A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (ARIMIDEX) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer, 32A: 404-412, 1996.
92. Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M, Azab, M., Webster, A, and Plourde, P. V. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. J. Clin. Oncol., 14: 2000-2011, 1996.
93. Bhatnagar, A S., Hausler, A., Schieweck, K., Lang, M., and Bowman, R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 37: 1021-1027, 1990.
94. Schieweck, K, Bhatnagar, A. S., Batzl, C., and Lang, M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem. Mol. Biol, 44: 633-636, 1993.
95. Demers, L. M., Lipton, A., Harvey, H. A., Kambic, K. B., Grossberg, H., Brady, C., and Santea, R. J. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J. Steroid Biochem. Mol. Biol., 44: 687-691, 1993.
96. Iveson, T. J., Smith, I. E., Ahem, J., Smithers, D. A., Trunet, P. F., and Dowsett, M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res, 53: 266-270, 1993.
97. Iveson, T. J., Smith, I. E., Ahem, J., Smithers, D A., Trunet, P. F., and Dowsett, M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocrinol. Metab., 77: 324-331, 1993.
98. Trunet, P F., Mueller, P., Bhatnagar, A. S., Dickes, I., Monnet, G., and White, G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor. CGS 20 267, in healthy male subjects. J. Clin. Endocrinol. Metab., 77: 319-323, 1993.
99. Bisagni, G., Coccoru, G., Scaglione, F., Fraschim, F., Pfister, C., and Trunet, P. F. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann. Oncol., 7: 99-102, 1996.
100. Wouters, W., Van Ginckel, R., Krekels, M., Bowden, C., and De Coster, R. Pharmacology of vorozole. J. Steroid Biochem Mol Biol., 44: 617-621, 1993.
101. De Coster, R., Van Ginckel, R. F., Callens, M. J. L., Goeminne, N. K. G., and Janssens, B. L. E. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res., 52: 1240-1244, 1992
102. van der Wall, E., Donker, T. H., de Frankrijker, E, Nortier, H. W. R, Thijssen, J. H. H., and Blankenstein, M. A. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res., 53: 4563-4566, 1993.
103. Wouters, W., Snoeek, E., and De Coster, R. Vorozole, a specific nonsteroidal aromatase inhibitor. Breast Cancer Res Treat., 30: 89-94, 1994.
104. Johnston, S. R. D., Smith, I. E., Doody, D., Jacobs, S., Robertshaw, H, and Dowsett, M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res., 54: 5875-5881, 1994.
105. Goss, P. E., Clark, R. M, Ambus, U., Weizel, H A. E., Wadden, N. A., Crump, M., Walde, D., Tye, L. M., De Coster, R., and Bruynseels, J. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin. Cancer Res., 1: 287-294, 1995.
106. Brodie, A. M. H., Banks, P. K., Inkster, S. E, Dowsett, M, and Coombes, R. C. Aromatase inhibitors and hormone-dependent cancers. J. Steroid Biochem. Mol. Biol, 37: 327-333, 1990.
107. Coombes, R. C., Wilkinson, J R., Bliss, J. M., Shah, P., Easton, D. F, and Dowsett, M. 4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis. Br. J. Cancer, 64: 247-250, 1991
108. Wiseman, L. R., and McTavish, D. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer Drugs, 45: 66-84, 1993.
109. Dowsett, M., Cunningham, D. C., Stein, R. C., Evans, S., Dehennin, L., Hedley, A., and Coombes, R C Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res., 49: 1306-1312, 1989.
110. Zilembo, N., Bajetta, E., Noberasco, C., Buzzoni, R., Vicario, G., Bono, A., Laffranchi, A., Biasi, G., Dolci, S., and Bichisao, E. Formestane' an effective first-line endocrine treatment for advanced breast cancer. J Cancer Res Clin. Oncol., 121: 378-382, 1995.
111. Cunningham, D., Powles, T. J., Dowsett, M, Hutchison, G., Brodie, A. M. H., Ford, H. T., Gazet, J-C., and Coombes, R. C. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother. Pharmacol, 20: 253-255, 1987.
112. Dowsett, M, Stein, R. C., and Coombes, R. C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem. Mol. Biol., 43: 155-159, 1992
113. Dowsett, M Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem. Mol. Biol, 37: 1037-1041, 1990
114. Dowsett, M., and Coombes, R. C Second generation aromatase inhibitor: 4-hydroxyandrostenedione. Breast Cancer Res. Treat, 30: 81-87, 1994
115. DiSalle, E., Ornati, G., Giudici, D., Lassus, M., Evans, T. R. J., and Coombes, R. C. Exemestane (FCE-24304), a new steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol., 43: 137-143, 1992.
116. Zaccheo, T, Giudici, D., Ornati, G., Panzeri, A, and di Salle, E. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur. J. Cancer, 27: 1145-1150, 1991.
117. Zaccheo, T., Giudici, D., and Di Salle, E. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem. Mol. Biol., 44: 677-680, 1993
118. Evans, T. R. J., Di Salle, E., Ornati, G., Lassus, M., Benedetti, M S., Pianezzola, E, and Coombes, R. C. Phase I and endocrine study if exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res., 52: 5933-5939, 1992.
119. Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariant, L, Orefice, S., Buzzoni, R., Di Bartolomeo, M., Di Leo, A., Laffranchj, A., and di Salle, E Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J. Cancer, 72: 1007-1012, 1995.
120. Henderson, D., Norbisrath, G., and Kerb, U, 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis. J Steroid Biochem., 24: 303-306, 1986.
121. Di Salle, E., Giudici, D., Briatico, G., and Omati, G. Novel irreversible aromatase inhibitors. Ann. N. Y. Acad. Sci., 595: 357-367, 1990.
122. Schweikert, H. U., Tunn, U. W., Habenicht, U-F., Arnold, J, Senge, T., Schulze, H., Schroder, F H, Blom, J. H. M., Ennemoser, O., Horniger, W., and Bartsch, G. Effects of estrogen deprivation on human benign prostatic hyperplasia J Steroid Biochem. Mol. Biol., 44: 573-576, 1993.
123. Geelen, J. A. A, Loozen, H J. J., Deckers, G. H., De Leeuw, R., Kloosterboer, H J, and Lamberts, S. W. J. ORG 33201: a new highly selective orally active aromatase inhibitor. J. Steroid Biochem. Mol. Biol., 44: 681-682, 1993.
124. Lang, M., Batzl, C., Furet, P, Bowman, R., Hausler, A., and Bhatnagar, A. S Structure-activity relationships and binding model of novel aromatase inhibitors. J. Steroid Biochem. Mol. Biol., 44: 421-428, 1993.
125. Di Salle, E., Giudici, D., Ornati, G., Briatico, G., D'Alessio, R., Villa, V, and Lombardi, P. 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J. Steroid Biochem Mol. Biol., 37: 369-374, 1990.
126. Di Salle, E., Briatico, G., Giudici, D., Ornati, G., Zaccheo, T., Buzzetti, F, Nesi, M., and Panzeri, A. Novel aromatase and 5α-reductase inhibitors. J. Steroid Biochem. Mol. Biol., 49: 289-294, 1994.
127. Johnston, J O., Wright, C. L, and Metcalf, B. W. Biochemical and endocrine properties of a mechanism-based inhibitor of aromatase. Endocrinology, 115: 776-785, 1984.
128. Puett, D, Brandt, M. E, Covey, D. F., and Zimniski, S. J. Characterization of a potent inhibitor of aromatase: inhibition of the rat ovarian enzyme and regression of estrogen-dependent mammary tumors by 10-propargylestr-4-ene3,17-dione., In: Baulieu, E. E., lacobelli, S., and McGuire, W. L. (eds.). Endocrinology and Malignancy, pp. 278-289. Park Ridge, NJ: The Parthenon Publishing Group Inc., 1986.
129. Longcope, C., Femino, A., and Johnston, J. O. Inhibition of periperal aromatization in baboons by an enzyme-activated aromatase inhibitor (MDL 18,962). Endocrinology, 122: 2007-2011, 1988.
130. Johnston, J O Biological characterization of 10-(2-propynyl) estr-4-ene3,17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase. Steroids, 50, 105-119, 1987.
131. Zimniski, S. J., Brandt, M. E., Covey, D. F., and Puett, D. Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor. Breast Cancer Res. Treat, 26: 15-21, 1993.
132. Zimniski, S. J., Brandt, M. E., Covey, D F., and Puett, D Inhibition of aromatase activity and of endocrine-responsive rumor growth by 10-propargylestr-4-ene-3,17-dione and its 17-propionate derivative. Steroids, 50: 135-146, 1987
133. Johnston, J. O., Wright, C. L., and Holbert, G. W Enzyme-activated inhibitors of steroidal hydroxylases. J Steroid Biochem. Mol. Biol, 52: 17-34, 1995.
134. Kitawaki, J, Kim, T., Kanno, H., Noguchi, T., Yamamoto, T., and Okada, H. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening J Steroid Biochem. Mol. Biol., 44: 667-670, 1993.
135. Evans, B. A. J., Stillman, S C., Hughes, I. A., Nicholls, P. J. and Smith, H. J Screening and determination of kinetic parameters of aromatase inhibitors using human genital skin fibroblasts. J. Enzym. Inhib., 7: 203-212, 1993.
136. Zhou, D., Pompon, D., and Chen, S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res., 50: 6949-6954, 1990.
137. Yue, W., Chen, S., and Brodie, A. Modified breast carcinoma model for evaluating aromatase inhibitors and other antitumor agents. Proc. Annu. Meet. Am. Assoc. Cancer Res., 35: 257, 1994.
138. Steele, V. E., Moon, R. C., Lubet, R A., Grubbs, C. J., Reddy, B. S., Wargovich, M, McCormick, D. L, Pereira, M. A., Crowell, J. A., Bagheri, D., Sigman, C. C., Boone, C. W., and Kelloff, G. J. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models' methods and results from the NCI Chemoprevention Drug Development Program. J. Cell. Biochem., 20: 32-54, 1994.
139. Bosland, M. C, and Prinsen, M. K. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz[a]anthracene, and 3,2′-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res., 50: 691-699, 1990.
140. Bosland, M. C., Prinsen, M. K., Dirksen, T. J. M, and Spit, B. J. Characterization of adenocarcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrosourea, 7,12-dimethylbenz[a]anthracene, and 3,2′-dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res., 50: 700-709, 1990.
141. Hammond, C. B. Menopause and hormone replacement therapy: an overview. Obstet. Gynecol, 87 (Suppl.); 2S-15S, 1996.
142. Sagraves, R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J. Clin. Pharmacol., 35 (Suppl.): 2S-10S, 1995.
143. Grodstein, F., and Stampfer, M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog. Cardiovasc. Dis., 38: 199-210, 1995.
144. Chow, M. S. S. Benefit/risk of estrogen therapy in cardiovascular disease. current knowledge and future challenges. J. Clin. Pharmacol., 35 (Supp;.): 11S-17S, 1995.
145. Simpson, E. R., Mahendroo, M. S, Nichols, J. E., and Bulun, S. E. Regulation of aromatase gene expression: relationship to breast cancer. Int Congr. Ser., 1064: 269-278, 1994
146. O'Neill, J. S., Elton, R. A., and Miller, W. R. Aromatase activity in adipose tissue from breast quadrants: a link with tumor site. Br. Med. J., 296: 741-743, 1988.
147. Bulun, S. E., Price, T M., Mahendroo, M. S., Aitken, J., and Simpson, E. R. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol. Metab., 77: 16222-1628, 1993.
148. Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore, M. W., Hinshelwood, M M., Graham-Lorence, S., Amarneh, B., Ito, Y., Fisher, C. R., Michael, M. D., Mendelson, C. R., and Bulun, S. E. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev., 15: 342-355, 1994.
149. Simpson, E. R., Merrill, J. C., Hollub, A. J., Graham-Lorence, S., and Mendelson, C. R. Regulation of estrogen biosynthesis by human adipose cells Endocr. Rev., 10: 136-148, 1989.
150. Reed, M. J. The role of aromatase in breast tumors. Breast Cancer Res. Treat., 30: 7-17, 1994.
151. Brodie, A. Aromatase and its inhibitors, an overview. J. Steroid Biochem. Mol. Biol., 40: 255-261, 1991.